ASTRIA THERAPEUTICS INC (ATXS) Stock News

NASDAQ:ATXS - US04635X1028 - Common Stock

7.52 USD

+0.52 (+7.43%)

Last: 9/5/2025, 8:00:01 PM

7.59 USD

+0.07 (+0.93%)

After Hours: 9/5/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ATXS Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 days ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025

10 days ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference

22 days ago - By: Zacks Investment Research

Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect?

25 days ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

a month ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan

a month ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit

2 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit

3 months ago - By: Benzinga - Mentions: PRE CPHI TLSA HCTI ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

3 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

3 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress

3 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Astria Therapeutics

Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference

4 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop

4 months ago - By: Astria Therapeutics

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

4 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

4 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology

4 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference

5 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

6 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

6 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

7 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

7 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

7 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

8 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

8 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

8 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

9 months ago - By: Benzinga - Mentions: AVGR KALV ATNF ANEB ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session